Published in Drug Week, October 27th, 2006
Study 1: Cardiovascular disease risk is reduced in patients with impaired glucose tolerance taking acarbose via the amelioration of the atherogenicity of low-density lipoprotein.
A recent study from Japan notes, "Acarbose, alpha-glucosidase inhibitor, is administered to control blood glucose levels. The drug also reduces the risk of cardiovascular disease, but the underlying mechanism is still to be elucidated."
"We therefore hypothesized that treatment with acarbose ameliorates the atherogenecity of low-density lipoprotein (LDL), a key molecule in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.